Literature DB >> 17414317

Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

German G Gomez1, Carol A Kruse.   

Abstract

Two immunoresistant (IR) glioma cell variants, 13-06-IR29 and 13-06-IR30, were cloned from 13-06-MG glioma cell populations after receiving continuous immunoselective pressure from multiple alloreactive cytotoxic T lymphocyte (aCTL) preparations. Reapplication of aCTL immunoselective pressure to the IR clones, displaying a partial regain in sensitivity to aCTL after removal of the selective pressure, restored the resistance. The IR variants exhibited cross-resistance to non-human leukocyte antigen (HLA)-restricted effector cells and gamma-irradiation, but not to carmustine. The IR clones were characterized for factors that might contribute to the immunoresistance. The aCTL adhesion to extracellular matrix extracts derived from either the IR clones or the parental cells was similar and not impaired. Furthermore, aCTL binding to parental cells and IR clones was equal. Down-regulation of the cell recognition molecules, class I HLA or intercellular adhesion molecule-1 (ICAM-1), that would inhibit their recognition by aCTL was not observed on the IR clones. The down-regulation of Fas by the IR clones correlated with their resistance to FasL-induced apoptosis. HLA-G or FasL that might provide an immunotolerant environment or provide a means of counterattack to aCTL, respectively, were not associated with the IR phenotype. The aCTL, coincubated with the IR clones and parental cells, displayed up-regulation of multiple secreted cytokines. A significant up-regulation of bioactive transforming growth factor (TGF)-beta was observed in the IR clones compared with the parental cells. These data suggest that increased secretion of bioactive TGF-beta may inhibit aCTL lysis of the IR clones. Disruption of the TGF-beta signaling pathway may circumvent the resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414317      PMCID: PMC1894900          DOI: 10.1097/01.cji.0000211339.81211.25

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  76 in total

1.  Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase.

Authors:  C Choi; X Xu; J W Oh; S J Lee; G Y Gillespie; H Park; H Jo; E N Benveniste
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.

Authors:  C A Kruse; L T Beck
Journal:  Biotechnol Appl Biochem       Date:  1997-06       Impact factor: 2.431

Review 3.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.

Authors:  Daniel J Brat; Anita C Bellail; Erwin G Van Meir
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

4.  The HLA-G gene is expressed at a low mRNA level in different human cells and tissues.

Authors:  M Onno; T Guillaudeux; L Amiot; I Renard; B Drenou; B Hirel; M Girr; G Semana; P Le Bouteiller; R Fauchet
Journal:  Hum Immunol       Date:  1994-09       Impact factor: 2.850

5.  Heterogeneous mechanisms of human cytotoxic T lymphocyte generation. II. Differential effects of IL-6 on the helper cell-independent generation of CTL from CD8+ precursor subpopulations.

Authors:  H Z Bass; N Yamashita; L T Clement
Journal:  J Immunol       Date:  1993-09-15       Impact factor: 5.422

6.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

Review 7.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

8.  TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet.

Authors:  Jack T Lin; Stacey L Martin; Luxi Xia; James D Gorham
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

9.  Cytotoxic T cells specifically induce Fas on target cells, thereby facilitating exocytosis-independent induction of apoptosis.

Authors:  M M Simon; P Waring; M Lobigs; A Nil; T Tran; R T Hla; S Chin; A Müllbacher
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

10.  Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.

Authors:  C A Kruse; D H Mitchell; K O Lillehei; S D Johnson; E L McCleary; G E Moore; S Waldrop; G W Mierau
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

View more
  12 in total

Review 1.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis.

Authors:  Zheng-Lin Ou; Zhen Luo; Wei Wei; Shuai Liang; Tai-Long Gao; Ye-Bin Lu
Journal:  RNA Biol       Date:  2019-08-12       Impact factor: 4.652

4.  Role of IL-17 in Glioma Progression.

Authors:  Prahlad Parajuli; Sandeep Mittal
Journal:  J Spine Neurosurg       Date:  2013-10-18

5.  Generation and immunologic functions of Th17 cells in malignant gliomas.

Authors:  Manjeera Paladugu; Archana Thakur; Lawrence G Lum; Sandeep Mittal; Prahlad Parajuli
Journal:  Cancer Immunol Immunother       Date:  2012-07-01       Impact factor: 6.968

Review 6.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

7.  Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.

Authors:  Courtney Crane; Amith Panner; Russell O Pieper; Jack Arbiser; Andrew T Parsa
Journal:  J Immunother       Date:  2009 Jul-Aug       Impact factor: 4.456

8.  Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

Authors:  German G Gomez; Michelle J Hickey; Richard Tritz; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2008-06

9.  Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.

Authors:  Michelle J Hickey; Colin C Malone; Kate L Erickson; Amy Lin; Horacio Soto; Edward T Ha; Shuichi Kamijima; Akihito Inagaki; Masamichi Takahashi; Yuki Kato; Noriyuki Kasahara; Barbara M Mueller; Carol A Kruse
Journal:  Clin Cancer Res       Date:  2013-06-18       Impact factor: 12.531

10.  PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion.

Authors:  Sebastian Seufert; Roland Coras; Christian Tränkle; Darius P Zlotos; Ingmar Blümcke; Lars Tatenhorst; Michael T Heneka; Eric Hahnen
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.